Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads

Journal of Theoretical Biology

Volumn 192, Issue 1, 1998, Pages 81-98

  Wein, Lawrence M ^a   D'Amato, Rebecca M ^b   Perelson, Alan S ^c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL MODEL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD; VIRUS MUTANT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0032492830     PISSN: 00225193     EISSN: None     Source Type: Journal    
DOI: 10.1006/jtbi.1997.0622     Document Type: Article

References (72)

1. + T cell homeostasis and function in advanced HIV disease. Science 277, 112-116.
2. BONHOEFFER, S. & NOWAK, M. (1997). Pre-existence and emergence of drug resistance in HIV-1 infection. Proc. Royal Soc. B 264, 631-637.
3. BONHOEFFER, S., COFFIN, J. M. & NOWAK, M. A. (1997). Human immunodeficiency virus drug therapy and virus load. J. Virol. 71, 3275-3278.
4. BRICHACEK, B., SWINDELLS, S., JANOFF, E. N., PIRRUCCELLO, S. & STEVENSON, M. (1996). Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J. Infect. Dis. 174, 1191-1199.
5. CAO, Y., DIETERICH, D., THOMAS, P. A., HUANG, Y. X., MIRABILE, M. & Ho, D. D. (1992). Identification and quantitation of HIV-1 in the liver of patients with AIDS. AIDS 6, 65-70.
6. CHEESEMAN, S. H., DAVARO, R. E. & ELLISON, R. T. 3RD (1996). Hepatitis B vaccination and plasma HIV-1 RNA. N. Engl. J. Med. 334, 1272.
7. CHUN, T. W., CARRUTH, L., FINZI, D., SHEN, X., DIGIUSEPPE, J. A., TAYLOR, H., et al. (1997). Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188.
8. CONDRA, J. H. (1995). Evidence for the existence of long-lived genetic reservoirs of HIV-1 in infected patients. J. AIDS and Human Retrovirology 10S3, S40.
9. CROW, J.F. & KIMURA, M. (1970). An Introduction to Population Genetics Theory. NY: Harper & Row.
10. DE BOER, R.J. & BOUCHER, C. A. B. (1996). Anti-CD4 therapy for AIDS suggested by mathematical models. Proc. Roy. Soc. London B 263, 899-905.
11. DE BOER, R J. & PERELSON A. S. (1997). Target cell limited and immune control models of HIV infection: A comparison. J. theoret. Biol. (in press).
12. DE JONG, M. D., VEENSTRA, J., STILIANAKIS, N. I., SCHUURMAN, R., LANGE, J. M. A., DE BOER, R. J., & BOUCHER, C. A. B. (1996). Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of HIV-1 RNA load suppression by zidovudine. Proc. Natl. Acad. Sci. USA 93, 5501-5506.
13. EMBRETSON, J., ZUPANCIC, M., BENEKE, J., TILL, M., WOLINSKY, S., RIBAS, J. L., et al. (1993). Analysis of human immunodeficiency virus-infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single-cell resolution. Proc. Natl. Acad. Sci. USA 90, 357-361.
14. ERON, J. J., BENOIT, S. L., JEMSEK, J., MACARTHUR, R. D., SANTANA, J., QUINN, J. B., et al. (1995). Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimeter. N. Engl. J. Med. 333, 1662-1669.
15. ESSUNGER, P., MARKOWITZ, M., Ho, D. D. & PERELSON, A. S. (1997). Efficacy of drug combination and dosing regimen in antiviral therapy. Intl. Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, FL, June, 1997, Antiviral Therapy, Abs. 73.
16. FINZI, D., HERMANKOVA, M., PIERSON, T., CARRUTH, L. M., BUCK, C., CHAISSON, R. E., et al. (1997). Identification of a reservoir for HIV-1 patients on highly active antiretroviral therapy. Science 278, 1295-1300.
17. FROST, S. D. W. & MCLEAN, A. R. (1994). Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 8, 323-332.
18. GARTNER, MARKOVITS, P., MARKOVITZ, D. M., KAPLAN, M. H., GALLO, R. C. & POPOVIC, M. (1986). The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233, 215-219.
19. GOLETTI, D., WEISSMAN, D., JACKSON, R. W., GRAHAM, N. M., VLAHOV, D., KLEIN, R. S., et al. (1996). Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J. Immunol. 157, 1271-1278.
20. GOUDSMIT, J., DE RONDE, A., Ho, D. D. & PERELSON, A. S. (1996). Human immunodeficiency virus fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J. Virol. 70, 5662-5664.
21. GULICK, R. M., MELLORS, J. W., HAVLIR, D., ERON, J. J., GONZALEZ, C., McMAHON, D., et al. (1997). Treatment with indinavir, zidovudine (ZDV) and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New Engl. J. Med. 337, 734-739.
22. GULICK, R. M., MELLORS, J., HAVLIR, D., ERON, J., GONZALEZ, C., MCMAHON, D., et al. (1996). Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). XI International Conference on AIDS, Vancouver, 11 July 1996, Abstr. Th.B.931.
23. HAASE, A. T., HENRY, K., ZUPANCIC, M., SEDGEWICK, G., FAUST, R. A., MELROE, H., et al. (1996). Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274, 985-989.
24. HALL, D. & CONWAY, B. (1997). Induction therapy: proof of concept by withdrawal of didanosine from zidovudine plus nevirapine plus didanosine. Intl. Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, FL, 25-28 June 1997, Abstr. 130.
25. HARRIGAN, R., STONE, C., GRIFFIN, P., BLOOR, S., TISDALE, M., LARDER, B. & C. N. A. A. 2001 Trial Team (1997). Antiretroviral activity and resistance profile of the carbocyclic nucleoside HIV reverse transcriptase inhibitor 1592U89. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 23 January, 1997, Abstr. 15.
26. HAVLIR, D. V. & RICHMAN, D. D. (Protocol Chairs): ACTG 343 (1996). A prospective randomized double blind trial of three maintenance regimens for HIV infected subjects receiving induction therapy with zidovudine, lamivudine and indinavir (draft). 1996.
27. HAVLIR, D. V., EASTMAN, S., GAMST, A. & RICHMAN, D. D. (1996). Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients. J. Virol. 70, 7894-7899.
28. 3. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 26 January, 1997, Abstr. LB7.
29. Ho, D. D. (1995). Time to hit HIV, early and hard. New Eng. J. Med. 333, 450-451.
30. Ho, D. D., ROTA, T.R. & HIRSCH, M. S. (1986). Infection of monocyte-macrophages by human T lymphotropic virus type III. J. Clin. Invest. 77, 1712-1715.
31. Ho, D. D., NEUMANN, A. U., PERELSON, A. S., CHEN, W., LEONARD, J. M. & MARKOWITZ, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
32. KEPLER, T. B. & PERELSON, A. S. (1998). Drug concentration heterogeneity facilitates the evolution of drug resistance (submitted).
33. KLENERMAN, P. PHILLIPS, R. E., RINALDO, C. R., WAHL, L. M., OGG, G., MAY, R. M., MCMICHAEL, A. J. & NOWAK, M. A. (1996). Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. Proc. Natl. Acad. Sci USA 93, 15323-15328.
34. KOENIG, S., GENDELMAN, H. E., ORENSTEIN, J. M., DAL CANTO, M. C., PEZESHKPOUR, G. H., YUNGBLUTH, M., et al. (1986). Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233, 1089-1093.
35. KOVACS, J. A., BASELER, M., DEWAR, R. J., VOGEL, S., DAVEY, JR, R. T., FALLOON, J., et al. (1995). Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 332, 567-575.
36. LANE, H. C., DEPPER, J., GREENE, W. C., WHALEN, G., WALDMANN, T. A. & FAUCI, A. S. (1985). Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. New Engl. J. Med. 313, 79-84.
37. LEDERMAN, M., CONNICK, E., LANDAY, A., KESSLER, H., KURITZKES, D., ST., CLAIR, M., et al. (1997). Partial immune reconstitution after 12 weeks of HAART (AZT, 3TC, Ritonavir): preliminary results of ACTG 315. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 26 January, 1997, Abstr. LB13.
38. LOVEDAY, C., KAYE, S., TENANT-FLOWERS, M., SEMPLE, M., AYLIFFE, U., WELLER, I. V. D. & TEDDER, R. S. (1995). HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 345, 820-824.
39. MANSKY, L. M. & TEMIN, H. M. (1995). Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69, 5087-5094.
40. MARKOWITZ, M., CAO, Y., HURLEY, A., O'DONOVAN, R., HEATH-CHIOZZI, M., LEONARD, J., et al. (1996). Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1. XI International Conference on AIDS, Vancouver, 11 July 1996, Abstr. Th.B.933.
41. MCLEAN, A. R. & FROST, S. D. W. (1995). Zidovudine and HIV: mathematical models of within-host population dynamics. Rev. Med. Virol. 5, 141-147.
42. MCLEAN, A. R. & MICHIE, C. A. (1995). In vivo estimates of division and death rates of human T lymphocytes. Proc. Natl. Acad. Sci. USA 92, 3707-3711.
43. MCLEAN, A. R. & NOWAK, M. A. (1992). Competition between zidovudine sensitive and resistant strains of HIV. AIDS 6, 71-79.
44. MCLEAN, A. R., EMERY, V. C., WEBSTER, A. & GRIFFITHS, P. D. (1991). Population dynamics of HIV within an individual after treatment with zidovudine. AIDS 5, 485-489.
45. MELLORS, J. W., RINALDO, C. R. JR, GUPTA, P., WHITE, R. M., TODD, J. A. & KINGSLEY, L. A. (1996). Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167-1170.
46. MOHRI, H., BONHOEFFER, S., MONARD, S., PERELSON, A. S. & Ho, D. D. (1998). Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science 297, 1223-1227.
47. MOLLA, A., KORNEYEVA, M., GAO, Q., VASAVANONDA, S., SCHIPPER, P. J., Mo, H., et al. (1996). Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 2, 760-766.
48. MORENO, P., REBOLLO, M. J., PULIDO, F., RUBIO, R., NOREIGA, A. R. & DELGADO, R. (1996). Alveolar macrophages are not an important source of viral production in HIV-1 infected patients. AIDS 10, 682-684.
49. NAJERA, I., HOLGUIN, A., QUINONES-MATEU, M. E., MUNOZ-FERNANDEZ, M. A., NAJERA, R., LOPEZ-GALINDEZ, C. & DOMINGO, E. (1995). Pol gene quasispecies of human immunodeficiency virus: Mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69, 23-31.
50. NOWAK, M. A., BONHOEFFER, S., SHAW, G. M. & MAY, R. M. (1997). Anti-viral drug treatment: dynamics of resistance in free virus and infected cell population. J. theor. Biol. 184, 203-217.
51. NOWAK, M. A., BONHOEFFER, S., LOVEDAY, C., BALFE, P., SEMPLE, M., KAYE, S., et al. (1995). HIV results in the frame: Results confirmed. Nature 375, 193.
52. O'BRIEN, W. A., GROVIT-FERBAS, K., NAMAZI, A., OVCAK-DERZIC, S., WANG, H. J., PARK, J., et al. (1995). Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86, 1082-1089.
53. ORENSTEIN, J. M., Fox, C. & WAHL, S. M. (1997). Macrophages as a source of HIV during opportunistic infections. Science 276, 1857-1861.
54. PERELSON, A. S. (1989). Modeling the interaction of HIV with the immune system. In: Mathematical and Statistical Approaches to AIDS Epidemiology, (Castillo-Chavez, C., ed.). Lect. Notes in Biomath., Vol. 83, pp. 350-370. New York: Springer-Verlag.
55. + T cells. Math. Biosci. 114, 81-125.
56. PERELSON, A. S., NEUMANN, A. U., MARKOWITZ, M., LEONARD, J. M. & Ho, D. D. (1995). HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 271, 1582-1586.
57. PERELSON, A. S., ESSUNGER, P.. CAO, Y., VESANEN, M., HURLEY, A., SAKSELA, K., et al. (1997). Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191.
58. PHILLIPS, A. N. (1996). Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 271, 497-499.
59. PIALOUX, G., FOURNIER, S., MOULIGNIER, A., POVEDA, J. D., CLAVEL, F. & DUPONT, B. (1997). Central nervous system (CNS) as sanctuary of HIV-1 in a patient treated with AZT + 3TC + indinavir. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 23 January, 1997, Abstr. 233.
60. + T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J. Exp. Med. 187 (in press).
61. + T-cell counts in HIV-infected patients. Ann. Int. Med. 124, 1039-1050.
62. SCHNITTMAN, S. M., LANE, H. C., GREENHOUSE, J., JUSTEMENT, J. S., BASELER, M. & FAUCI, A. S. (1990). Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc. Natl. Acad. Sci. U.S.A. 87, 6058-6062.
63. STANLEY, S. K., OSTROWSKI, M. A., JUSTEMENT, J. S., GANTT, K., HEDAYATI, S., MANNIX, M., et al. (1996). Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N. Engl. J. Med. 334, 1222-1230.
64. STAPRANS, S. I., HAMILTON, B. L., FOLLANSBEE, S. E., ELBEIK, T., BARBOSA, P., GRANT, R. M. & FEINBERG, M. B. (1995). Activation of virus replication after vaccination of HIV-1-infected individuals. J. Exp. Med. 182, 1727-1737.
65. STILIANAKIS, N. I., BOUCHER, C. A. B., DE JONG, M. D., VAN LEEUWEN, R., SCHUURMAN, R. & DE BOER, R. J. (1997). Clinical data sets on human immunodeficiency virus type 1 reverse transcriptase resistant mutants explained by a mathematical model. J. Virol. 71, 161-168.
66. VAN FURTH, R. (1992). In: Inflammation: Basic Principles and Clinical Correlates (Gallin, J. I., Goldstein, I. M. & Snyderman, S., eds), pp. 325-339. NY: Raven, Press.
67. WEI, X., GHOSH, S. K., TAYLOR, M. E., JOHNSON, V.A., EMINI, E. A., DEUTSCH, P., et al. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-123.
68. WEIN, L., M., ZENIOS, S. & NOWAK, M. A. (1997). Dynamic multidrug therapies for HIV: a control theoretic approach. J. theor. Biol. 185, 15-29.
69. WEIN, L. M., D'AMATO, R. M. & PERELSON, A. S. (1997). Mathematical considerations of induction and maintenance therapy for HIV-1. Los Alamos National Laboratory Technical Report LA-UR-97-2255.
70. WHITTLE, P. (1995). The outcome of a stochastic epidemic - a note on Bailey's paper. Biometrika 42, 116-122.
71. WONG, J. K., HEZAREH, M., GUNTHARD, H. F., HAVLIR, D. V., IGNACIO, C. C., SPINA, C. A. & RICHMAN, D. D. (1997a). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295.
72. WONG, J. K., GUNTHARD, H. F., HAVLIR, D. V., HAASE, A. T., ZHANG, Z. Q., KWOK, S., et al. (1997b). Reduction of HIV in blood and lymph nodes after potent antiretroviral therapy. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 26 January, 1997, Abstr. LB10.